Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin in Major Depressive Disorder (CLARITY)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Adult patients, aged 18 years and above~2. A clinical diagnosis of major depressive disorder (MDD)~3. Is being treated with one of the following SSRI or SNRI antidepressants as monotherapy:~   * Citalopram~  * Escitalopram~  * Paroxetine~  * Fluoxetine~  * Sertraline~  * Duloxetine~  * Venlafaxine~  * Desvenlafaxine~  * Venlafaxine XR~4. Has a history of inadequate response to antidepressant treatments~Exclusion Criteria:~1. Patient has a psychotic disorder other than MDD~2. Patient has current evidence of a serious and/or unstable neurologic, cardiovascular, respiratory, gastrointestinal, renal, hepatic, hematologic, or other medical disorder, including cancer or malignancies, which would affect the patient's ability to participate in the program~3. Patient has a history or symptoms of long QT syndrome~Patients will be evaluated at screening to ensure that all criteria for study participation are met. Patients may be excluded from the study based on these assessments (and specifically if it is determined that their baseline health and psychiatric condition do not meet all pre-specified entry criteria).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pimavanserin 34 mg + SSRI/SNRI (Type: EXPERIMENTAL): Drug- pimavanserin, 34 mg, taken as two 17 mg tablets, once daily by mouth All patients continued to receive selective serotonin reuptake inhibitor/serotonin norepinephrine reuptake inhibitor (SSRI/SNRI) antidepressants at a stable dose for the duration of the study.
- Placebo + SSRI/SNRI (Type: PLACEBO_COMPARATOR): Placebo, taken as two tablets, once daily by mouth All patients continued to receive selective serotonin reuptake inhibitor/serotonin norepinephrine reuptake inhibitor (SSRI/SNRI) antidepressants at a stable dose for the duration of the study.

Based on this trial design, predict the completion outcome and termination type (if applicable).